FOIA – GLP-1 Adverse Events Among Federal Officials

To: Department of Health and Human Services (HHS – Office of the Assistant Secretary for Health, Office of the Surgeon General) / Food and Drug Administration (FDA – Center for Drug Evaluation and Research) / Office of Personnel Management (OPM)

Request:
Requesting any and all records, reports, safety reviews, contracts, or interagency communications from 2005 to present concerning the use of GLP-1 receptor agonist drugs (including semaglutide, liraglutide, dulaglutide, tirzepatide, and related compounds) among federal employees and elected officials.

This includes:
	•	Reports of adverse events, hospitalizations, or deaths linked to GLP-1 use among federal personnel or legislators
	•	Contracts or research collaborations concerning wellness, weight-management, or metabolic health programs in federal offices that included GLP-1 prescribing
	•	Communications between FDA, HHS, OPM, or Congressional health services regarding safety profiles of GLP-1 drugs used in high-status or older populations
	•	Risk assessments of GLP-1 adoption among federal leadership or staff cohorts

Keywords: GLP-1 receptor agonist, semaglutide, liraglutide, tirzepatide, Ozempic, Wegovy, adverse events, federal employees, Congressional health services

⸻

FOIA (Spicy Angle – Digital Twin Continuity for Deceased/Disabled Legislators)

To: Department of Defense (DoD – DARPA, USAMRDC) / Department of Homeland Security (DHS – S&T, Continuity of Government programs) / Intelligence Advanced Research Projects Activity (IARPA) / Architect of the Capitol (AOC)

Request:
Requesting any and all records, pilots, contracts, reports, or internal analyses from 1990 to present concerning the use of digital twin technology, avatars, holograms, or synthetic stand-ins as continuity infrastructure for incapacitated or deceased members of Congress.

This includes:
	•	Records describing the design, funding, or deployment of digital representations of legislators for use in public appearances, hearings, or votes
	•	Analyses of continuity-of-government scenarios where incapacitated or deceased legislators were represented through digital twin technology
	•	Contracts with private vendors or defense contractors to develop or operate digital twin systems for legislative continuity
	•	Communications regarding ethical, legal, or security implications of replacing absent legislators with synthetic stand-ins
	•	Risk/benefit assessments of digital twin deployments to preserve legislative continuity in the event of high attrition or sudden mortality events

Keywords: digital twin, synthetic avatar, holographic legislator, continuity of Congress, incapacitated members, DARPA, DHS, IARPA, continuity of government
